Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-12-19
2006-12-19
Mosher, Mary E. (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C530S350000, C435S320100, C435S069100, C435S325000, C514S04400A
Reexamination Certificate
active
07151172
ABSTRACT:
The present invention is directed to nucleic acid molecules encoding attenuated, non-functional virion infectivity factor (vif) proteins. The nucleic acid molecules of the invention are inserted into recombinant expression vectors and administered to mammals in order to induce a cellular and humoral immune response to the encoded protein product.
REFERENCES:
patent: 4945050 (1990-07-01), Sanford et al.
patent: 5036006 (1991-07-01), Sanford et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5593972 (1997-01-01), Weiner et al.
patent: WO 90/11092 (1990-10-01), None
patent: WO 93/17706 (1993-09-01), None
patent: WO 93/23552 (1993-11-01), None
patent: WO 94/16737 (1994-08-01), None
patent: WO 95/05851 (1995-03-01), None
Ma et al. Journal of Virology. 1994; 68 (3): 1714-1720.
Ayyavoo V, et al. “Develpoment of genetic vaccines for pathogenic genes: construction of attenuated vif DNA immunization cassettes”,Aids, 1997, 11, pp. 1433-1444.
Kim, J. J. et al. “Development of a multicomponent candidate vaccine for HIV-1”,Vaccine, 1997, 15(8), pp. 879-883.
Miller, R. H. et al. “HIV accessory proteins as therapeutic targets”,Nature Medicine, 1997, 3(4), pp. 389-394.
Aldrovandi, et al., “Replication and Pathogenicity of Human Immunodeficiency Virus Type 1 Acessory Gene Mutants in SCID-hu Mice”,J. Virology, 1996, vol. 70, No. 3, pp. 1505-1511.
Ameisen, et al., “Antibody Response to the HIV-1 Regulatory GEI Products NEF, VIF, and VPR in HIV-1 Infectious Seronegative Individuals,”Int Conf. AIDS, 1989, vol. 5, p. 533.
Ayyavoo, et al., “Analysis of Genetic Heterogeneity, Antigenicity, and Biological Characteristics of HIV-1 in a Maternal Transmitter and Nontransmitter Patient Pair,”DNA and Cell Biology, 1996, vol. 15, No. 7, pp. 571-580.
Arya et al., “Three Novel Genes of Human T-lymphotropic Virus Type III: Immune Reactivity of their Products with Sera from Acquired Immune Deficiency Syndrome Patients,”Proc. Natl. Acad. Sci. USA, 1986, vol. 83, pp. 2209-2213.
Blanc et al., “Transcomplementation of VIF- HIV-1 Mutants in CEM Cells Suggests That VIF Affects Late Steps of the Viral Life Cycle,”Virology., 1993, vol. 193, pp. 186-192.
Borman et al., “Human Immunodeficiency Virus Type 1 Vif-Mutant Particles from Restrictive Cells: Role of Vif in Correct Particle Assembly and Infectivity,”J. Virol, 1995, vol. 69, No. 4, pp. 2058-2067.
Cullen et al., “Regulatory Pathways Governing HIV-1 Replication,”Cell, 1989, vol. 58, pp. 423-426.
Desrosiers, “HIV with Multiple Gene Deletions as a Live Attenuated Vaccine for AIDS,”AIDS Res. AndHuman Retroviruses, 1992, vol. 8, No. 3, pp. 411-421.
Dougherty et al., “Determination of the Rate of Base-Pair Substitution and Insertion Mutations in Retrovirus Replication,”J. Virol, 1988, vol. 62, No. 8, pp. 2817-2822.
Fisher et al., “Biologically Diverse Molecular Variants Within a Single Hiv-1 Isolate,”Nature, 1988, vol. 334, pp. 444-447.
Fynan et al., “Dna Vaccines: Protective Immunization by Parenteral, Mucosal, and Gene-gun Inoculations,”Proc. Natl. Acad. Sci. USA, 1993, vol. 90, pp. 11478-11482.
Gabuzda et al., “Role ofvifin Replication of Human Immunodeficiency Virus Type 1 in CD4+ T Lymphocytes,”J. Virol, 1992, vol. 66, No. 11, pp. 6489-6495.
Garrett et al., “Rev Activates Expression of the Human Immunodeficiency Virus Type 1vifandvprGene Products,”J. Virol, 1992, vol. 65, No. 3, pp. 1653-1657.
Gibbs et al., “Construction andIn VitroProperties of HIV-1 Mutants with Deletions in “Nonessential” Genes,”Aids Res. And Human Retroviruses, 1994, vol. 10, No. 4, pp. 343-350.
Goncalves et al., “Subcellular Localization of the Vif Protein of Human Immunodeficiency Virus Type 1,”J. Virol, 1994, vol. 68, No. 2, pp. 704-712.
Guy et al., “A Specific Inhibitor of Cysteine Proteases Impairs a Vif-Dependent Modification of Human Immunodeficiency Virus Type 1 Env Protein,”J. Virol, 1991, vol. 65, No. 3, pp. 1325-1331.
Hevey et al., “Complementation of Human Immunodeficiency Virus Type 1vifMutants in Some CD4+ T-Cell Lines,”Virus Res, 1994, vol. 33, pp. 269-280.
Kan et al., “Identification of HTLV-III/LAV sor Gene Product and Detection of Antibodies in Human Sera,”Science, 1986, vol. 231, pp. 1553-1555.
Lamhamedi et al., “Qualitative and Quantitative Analysis of Human Cytotoxic T-lymphocyte Responses to HIV-1 Proteins,”AIDS, 1992, vol. 6, No. 11, pp. 1249-1258.
Ma et al, “Cysteine Residues in the Vif Protein of Human Immunodeficiency Virus Type 1 Are essential for Viral Infectivity,”J. Virol, 1994, vol. 68, No. 3, pp. 1714-1720.
Mahalingam et al., “The Carboxy-Terminal Domain is Essential for Stability and Not for Virion Incorporation of HIV-1 Vpr into Virus Particles,”Virol, 1995, vol. 214, pp. 647-652.
Meyerhans et al., “Temporal Fluctuations in HIV Quasispecies in Vivo Are Not Reflected by Sequential HIV Isolations,”Cell, 1989, vol. 58, pp. 901-910.
Michael et al., “Defective Accessory Genes in a Human Immunodeficiency Virus Type 1-Infected Long-Term Survivor Lacking Recoverable Virus,”J. Virol, 1995, vol. 69, No. 7, pp. 4228-4236.
Nagashunmugam et al., “Cell-Free HIV-1Zr6vif Mutants Are Defective in Binding to Peripheral Blood Mononuclear Cells and in Internalization,”DNA Cell Biol., 1996, vol. 15, No. 5, pp. 353-361.
Oberste et al., “Conservation of Amino Acid Sequence Motifs in Lentivirus Vif Proteins,”Virus Gene, 1992, vol. 6, No. 1, pp. 95-102.
Pircher et al., “Viral Escape by Selection of Cytotoxic T Cell-Resistant Virus Variantsin Vivo,” Nature, 1985, vol. 346, pp. 629-633.
Ratner et al., “Complete Nucleotide Sequence of the AIDS Virus, HTLV-III,”Nature, 1985, vol. 313, pp. 277-284.
Sakai et al., “Cell Dependent Requirement of Human Immunodeficiency Virus Type 1 Vif Protein for Maturation of Virus Particles,”J. Virol, 1993, vol. 67, No. 3, pp. 1663-1666.
Schwartz et al., “Expression of Human Immunodeficiency Virus Type 1 vif and vpr mRNAs Is Rev-dependent and Regulated by Splicing,”Virol, 1991, vol. 183, pp. 677-686.
Schwander et al., “Prevalance of Antibodies to Recombinant Virion Infectivity Factor in the Sera of Prospectively Studied Patients with HIV-1 Infection,”J. of Medical Virol, 1992, vol. 36, pp. 142-146.
Shackett et al., “Analysis of the vif Gene of Feline Immunodeficiency Virus,”Virol, 1994, vol. 204, pp. 860-867.
Sodroski et al., “Replicative and Cytopathis Potential of HTLV-III/LAV withsorGene Deletions,”Science, 1986, vol. 231, pp. 1549-1553.
Sova et al., “Conservation of an Intact Human immunodeficiency Virus Type-1 vif gene In Vitro and In Vivo,”J. Virol, vol. 69, No. 4, pp. 2557.
Srinivasan et al., “Molecular Characterization of Human Immunodeficiency Virus from Zaire: Nucleotide Sequence Analysis Identifies Conserved and Variable Domains in the Envelope Gene,”Gene, 1987, vol. 52, pp. 71-82.
Tang et al., “Genetic Immunization is a Simple Method for Eliciting an Immune Response,”Nature, 1992, vol. 356, pp. 152-154.
Trono., “HIV Accessory Proteins: Leading Roles for the Supporting Cast,”Cell, 1995, vol. 82, pp. 189-192.
Ulmer et al., “Heterologous Protection Against Influenza by injection of DNA Encoding a Viral Protein,”Science, 1993, vol. 259, pp. 1745-1749.
Volsky et al., “the Human Immunodeficiency Virus Type 1vifGene: The Road from an Accessory to an Essential Role in Human Immunodeficiency Virus Type 1 Replication,”Curr. Topics Micro. Immunol., 1995, vol. 193, pp. 157-168.
von Schwedler et al., “vifIs Crucial for Human Immunodeficiency Virus Type 1 Proviral DNA Synthesis in Infected Cells,”J. Virol., 1993, vol. 67, No. 8, pp. 4945-4955.
Wang et al.,
Ayyavoo Velpandi
Nagashunmugam Thanadavarayan
Weiner David B.
Cozen O'Connor P.C.
Mosher Mary E.
Peng Bo
The Trustees of the University of Pennsylvania
LandOfFree
Attenuated vif DNA immunization cassettes for genetic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Attenuated vif DNA immunization cassettes for genetic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuated vif DNA immunization cassettes for genetic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3673469